Abstract
Malignancy can be accompanied by rheumatologic clinical findings, and these can occur prior to, concurrently with, or after a diagnosis of cancer. Certain clinical information helps to differentiate paraneoplastic symptoms from those more characteristic of classic rheumatologic disorders such as rheumatoid arthritis or systemic lupus erythematosus. Clinicians need to have a higher level of suspicion for malignancy in a patient with rheumatologic manifestations in certain populations. This may be the case in patients with a personal or family history of malignancy, atypical presentations of rheumatologic disorders, and certain clinical situations (such as hypertrophic osteoarthropathy, carcinoma polyarthritis, dermatomyositis, and unilateral sacroiliitis). The current standard of care for patients with a rheumatologic disorder with a known paraneoplastic association (i.e., dermatomyositis) is age-appropriate cancer screening. This review is designed to guide the physician to musculoskeletal signs and symptoms that may be paraneoplastic in origin. Additionally, when the clinician understands current information regarding malignant associations, it will help them decide when it may be appropriate to pursue further investigative work-up or evaluate for recurrence of a known primary tumor.
Keywords: neoplastic process, Hypertrophic osteoarthropathy, Vasculitis, Dermatomyositis, lymphoma
Current Cancer Therapy Reviews
Title: Update on the Rheumatologic Manifestations of Malignancy
Volume: 3 Issue: 3
Author(s): Lianne Marks, Clifton D. Fuller, Parag Sanghvi, Melva Pinn and Charles R. Thomas
Affiliation:
Keywords: neoplastic process, Hypertrophic osteoarthropathy, Vasculitis, Dermatomyositis, lymphoma
Abstract: Malignancy can be accompanied by rheumatologic clinical findings, and these can occur prior to, concurrently with, or after a diagnosis of cancer. Certain clinical information helps to differentiate paraneoplastic symptoms from those more characteristic of classic rheumatologic disorders such as rheumatoid arthritis or systemic lupus erythematosus. Clinicians need to have a higher level of suspicion for malignancy in a patient with rheumatologic manifestations in certain populations. This may be the case in patients with a personal or family history of malignancy, atypical presentations of rheumatologic disorders, and certain clinical situations (such as hypertrophic osteoarthropathy, carcinoma polyarthritis, dermatomyositis, and unilateral sacroiliitis). The current standard of care for patients with a rheumatologic disorder with a known paraneoplastic association (i.e., dermatomyositis) is age-appropriate cancer screening. This review is designed to guide the physician to musculoskeletal signs and symptoms that may be paraneoplastic in origin. Additionally, when the clinician understands current information regarding malignant associations, it will help them decide when it may be appropriate to pursue further investigative work-up or evaluate for recurrence of a known primary tumor.
Export Options
About this article
Cite this article as:
Lianne Marks , Clifton D. Fuller , Parag Sanghvi , Melva Pinn and Charles R. Thomas , Update on the Rheumatologic Manifestations of Malignancy, Current Cancer Therapy Reviews 2007; 3 (3) . https://dx.doi.org/10.2174/157339407781368378
DOI https://dx.doi.org/10.2174/157339407781368378 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting TNF-Alpha in HIV-1 Infection
Current Drug Targets The Therapeutic Potential of PhospholipaseA2 Inhibitors in Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Chemical Modifications of Ketoprofen (NSAID) in Search of Better Lead Compounds: A Review of Literature From 2004-2016
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Bone Modulating Bioactive Natural Compounds: Review
Current Bioactive Compounds Nerve Growth Factor: A Focus on Neuroscience and Therapy
Current Neuropharmacology Transdermal Anti-inflammatory Delivery for Solid Lipid Nanoparticles of Ketoprofen by Microwave-assisted Microemulsion
Recent Advances in Inflammation & Allergy Drug Discovery Spontaneous (Autoimmune) Chronic Urticaria in Children: Current Evidences, Diagnostic Pitfalls and Therapeutic Management
Recent Patents on Inflammation & Allergy Drug Discovery Nanotechnologies for Anti-Inflammatory RNAi-Based Gene Silencing Strategies
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Update on the Biologic Role of the Vitamin D Endocrine System
Current Vascular Pharmacology Connecting A Tumor to the Environment
Current Pharmaceutical Design ADAM8 in Allergy
Inflammation & Allergy - Drug Targets (Discontinued) Methotrexate in the Treatment of Psoriasis and Rheumatoid Arthritis: Mechanistic Insights, Current Issues and Novel Delivery Approaches
Current Pharmaceutical Design Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry The Socioeconomic Effects of Uncontrolled Hypertension
Current Vascular Pharmacology Apoptosis-Inducing Activity of the S100A8/A9 Heterodimer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Endotherapia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Mechanisms of Developing Post-Traumatic Stress Disorder: New Targets for Drug Development and Other Potential Interventions
CNS & Neurological Disorders - Drug Targets The Relationship Between Focal and Generalized Bone Loss in Rheumatoid Arthritis
Current Rheumatology Reviews miRNA-146a Improves Immunomodulatory Effects of MSC-derived Exosomes in Rheumatoid Arthritis
Current Gene Therapy